ProCE Banner Activity

CME

A New Era of Immunotherapy in Small-Cell Lung Cancer

Multimedia
Watch this CME-certified video module of 2 lung cancer experts discussing recent advances in immunotherapy for the treatment of SCLC as they apply to a series of patient cases.

Physicians: Maximum of 0.50 AMA PRA Category 1 Credit

Released: August 08, 2019

Expiration: August 07, 2020

No longer available for credit.

Share

Faculty

Anna F. Farago

Anna F. Farago, MD, PhD

Assistant Professor of Medicine
Department of Medicine
Harvard Medical School
Assistant in Medicine
Division of Hematology/Oncology
Department of Medicine
Massachusetts General Hospital
Boston, Massachusetts

Leora Horn

Leora Horn, MD, MSc

Assistant Professor, Hematology Oncology/Medicine
Vanderbilt Ingram Cancer Center
Vanderbilt University
Nashville, Tennessee

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Bristol Myers Squibb

Genentech TEXT Only

Target Audience

This program is intended for physicians and other healthcare providers who care for patients with small-cell lung cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Evaluate the available efficacy and safety data on immunotherapies and their clinical implications for current therapy decisions in patients with SCLC at all disease stages
  • Plan treatment strategies for patients with SCLC that include immune checkpoint inhibitors
  • Differentiate the mechanisms of action and clinical properties of antibody–drug conjugates and other targeted therapies for the treatment of patients with SCLC

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty Disclosure

Primary Author

Anna F. Farago, MD, PhD

Assistant Professor of Medicine
Department of Medicine
Harvard Medical School
Assistant in Medicine
Division of Hematology/Oncology
Department of Medicine
Massachusetts General Hospital
Boston, Massachusetts

Anna F. Farago, MD, PhD, has disclosed that she has received funds for research support from AbbVie, AstraZeneca, Bayer, Bristol-Myers Squibb, Genentech, Loxo, Merck, and PharmaMar and consulting fees from AbbVie, AstraZeneca, Bayer, Boehringer Ingelheim, Genentech, and Loxo.

Leora Horn, MD, MSc

Assistant Professor, Hematology Oncology/Medicine
Vanderbilt Ingram Cancer Center
Vanderbilt University
Nashville, Tennessee

Leora Horn, MD, MSc, FRCPC, has disclosed that she has received consulting fees from AstraZeneca, EMD Serono, Genentech, Incyte, Merck, and Xcovery and funds for research support from Boehringer Ingelheim, Bristol-Myers Squibb, and Xcovery.

Staff Disclosure

Staff

Rachael M. Andrie, PhD

Clinical Editor

Rachael M. Andrie, PhD, has no relevant conflicts of interest to report.

Jason J. Everly, PharmD

Jason J. Everly, PharmD, BCOP, CHCP, has no relevant conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Tina B. Stacy, PharmD, FACEHP, BCOP, CHCP

Executive Vice President, Educational Strategy
General Manager, Oncology

Tina B. Stacy, PharmD, FACEHP, BCOP, CHCP, has no relevant conflicts of interest to report.

June Wasserstrom,

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 0.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from August 08, 2019, through August 07, 2020:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve participants’ preparedness to integrate novel immunotherapies and targeted agents into the treatment of patients with small-cell lung cancer.